Dupixent® (dupilumab) recommended for eu approval by the chmp to treat patients with copd

Recommendation for adults with uncontrolled copd with raised blood eosinophils based on data from two landmark phase 3 trials demonstrating dupixent significantly reduced exacerbations and improved lung function

REGN Ratings Summary

REGN Quant Ranking